1. [CASE 1 — QUESTION 1]
A 34-year-old healthy male is scheduled for elective laparoscopic cholecystectomy under general anesthesia. The anesthesiologist plans to use isoflurane as the primary maintenance agent. During the pre-anesthetic briefing, a resident asks what the minimum alveolar concentration (MAC) of isoflurane tells the clinician about its potency and what endpoint it predicts.
Which of the following best defines MAC and its clinical utility?
A) MAC is the alveolar concentration of an inhaled agent that produces unconsciousness in 50% of patients during verbal command testing, serving as a measure of hypnotic potency.
B) MAC is the alveolar concentration of an inhaled agent that prevents movement in response to a surgical incision in 50% of patients, serving as the standard measure of inhaled anesthetic potency.
C) MAC is the alveolar concentration of an inhaled agent that eliminates all autonomic responses to surgical stimulation in 100% of patients, used to guide intraoperative vasopressor dosing.
D) MAC is the end-tidal concentration of an inhaled agent required to maintain bispectral index (BIS) below 60 in 50% of patients, used as a real-time monitor of anesthetic depth.
ANSWER: B
Rationale:
Option B is correct. MAC is defined as the minimum alveolar concentration of an inhaled anesthetic at 1 atmosphere that prevents purposeful movement in response to a standardized surgical stimulus (skin incision) in 50% of subjects. It is the primary index of inhaled anesthetic potency, analogous to the ED50 for inhaled agents, and is used clinically to compare agents and guide dosing during maintenance.
Option A: Option A is incorrect because MAC measures the response to surgical incision, not response to verbal command; the endpoint for verbal command is MAC-awake, a distinct and lower value (approximately 0.3–0.5 × MAC).
Option C: Option C is incorrect on two counts: MAC is defined at the 50% population response level, not 100%, and it targets movement suppression, not autonomic response elimination; MAC-BAR (blocking autonomic response) is a separate, higher concentration.
Option D: Option D is incorrect because MAC is defined by clinical movement response to incision, not by BIS monitoring; BIS is a processed EEG index that correlates with anesthetic depth but is not used in the definition of MAC.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient from Question 1, the resident asks about induction speed. The attending explains that isoflurane has a blood/gas partition coefficient of 1.4, compared to desflurane at 0.45 and halothane at 2.4.
Which of the following correctly explains how the blood/gas partition coefficient determines the speed of inhalational induction?
A) A higher blood/gas partition coefficient produces faster induction because more agent dissolves in blood, rapidly raising brain partial pressure.
B) A higher blood/gas partition coefficient produces faster induction because the agent is less soluble in tissues, allowing earlier equilibration with alveolar gas.
C) The blood/gas partition coefficient has no meaningful effect on induction speed; onset is determined entirely by the inspired concentration and fresh gas flow rate.
D) A lower blood/gas partition coefficient produces faster induction because the agent is less soluble in blood, allowing alveolar partial pressure to rise quickly and equilibrate with brain partial pressure sooner.
ANSWER: D
Rationale:
Option D is correct. The blood/gas partition coefficient is the primary determinant of inhalational induction speed. A low coefficient means the agent has low blood solubility; blood becomes saturated rapidly without absorbing large quantities of agent from the alveolus, so alveolar partial pressure rises quickly. Because brain partial pressure equilibrates with alveolar partial pressure, low blood solubility translates directly to faster onset. Desflurane (0.45) and nitrous oxide (0.47) have the lowest coefficients and fastest equilibration; halothane (2.4) and older agents with high solubility have the slowest onset.
Option A: Option A is incorrect and inverts the relationship: high blood solubility causes blood to act as a large reservoir, absorbing agent and slowing the rise in alveolar partial pressure, thereby delaying onset.
Option B: Option B is incorrect because it conflates blood solubility with tissue solubility and reverses the direction of the effect.
Option C: Option C is incorrect; while inspired concentration and fresh gas flow do influence the rate of rise of alveolar concentration (FA/FI ratio), the blood/gas partition coefficient is a fundamental independent determinant of induction speed that cannot be dismissed.
3. [CASE 1 — QUESTION 3]
The same resident asks about factors that alter MAC. The attending notes that MAC is not fixed and is modified by patient physiological state, concurrent medications, and other variables.
Which of the following factors is correctly paired with its effect on MAC?
A) Chronic alcohol use disorder increases MAC, reflecting CNS tolerance to depressant agents through upregulation of excitatory receptors and downregulation of inhibitory receptors.
B) Advanced age increases MAC, as older patients require higher anesthetic concentrations to suppress spinal cord motor responses to surgical stimulation.
C) Hypothermia increases MAC, because reduced body temperature increases the metabolic demand for anesthetic agent at the site of action.
D) Acute opioid administration increases MAC, because opioids activate excitatory mu-receptor pathways in the spinal cord that compete with inhaled agent suppression of movement.
ANSWER: A
Rationale:
Option A is correct. Chronic alcohol use disorder increases MAC through neuroadaptation: sustained ethanol exposure downregulates inhibitory GABA-A receptor function and upregulates excitatory NMDA receptor activity, producing tolerance to CNS depressants including inhaled anesthetics. Clinically, patients with chronic alcohol use disorder require meaningfully higher inhaled agent concentrations to achieve the same anesthetic endpoint.
Option B: Option B is incorrect and reverses the direction: advanced age decreases MAC, typically by approximately 6% per decade above age 40, reflecting reduced neuronal density and decreased CNS reserve.
Option C: Option C is incorrect and also reverses the direction: hypothermia decreases MAC in a roughly linear fashion (approximately 5% per degree Celsius decrease in core temperature), likely through temperature-dependent changes in membrane lipid dynamics and ion channel kinetics.
Option D: Option D is incorrect: acute opioid administration decreases MAC (MAC-sparing effect) through mu-receptor-mediated inhibition of spinal cord nociceptive transmission, reducing the anesthetic concentration required to prevent movement to incision.
4. [CASE 1 — QUESTION 4]
The anesthesiologist decides to co-administer nitrous oxide at 70% with isoflurane at induction to accelerate onset. A medical student observing the case asks about the second gas effect.
Which of the following best explains the mechanism of the second gas effect?
A) Nitrous oxide displaces nitrogen from the alveolus, increasing the partial pressure gradient for the volatile agent between the circuit and the alveolus, accelerating delivery from the vaporizer.
B) Nitrous oxide, because of its high blood solubility, rapidly saturates pulmonary capillary blood and reduces cardiac output, slowing blood flow through the lungs and allowing more time for volatile agent uptake.
C) Rapid uptake of the high-volume nitrous oxide from the alveolus concentrates the remaining volatile agent in the alveolus and simultaneously increases alveolar ventilation by drawing in fresh gas, both effects accelerating volatile agent uptake.
D) Nitrous oxide activates NMDA receptors in the brainstem, producing a synergistic reduction in MAC of the co-administered volatile agent that is disproportionate to its own anesthetic contribution.
ANSWER: C
Rationale:
Option C is correct. The second gas effect has two simultaneous components. First, the concentration effect: rapid absorption of the large volume of nitrous oxide from the alveolus concentrates the remaining volatile agent (the "second gas") in a smaller alveolar volume, raising its partial pressure above what would be achieved by the inspired concentration alone. Second, the augmented ventilation (or traction) effect: as the large nitrous oxide volume is absorbed, the reduction in alveolar gas volume creates a relative negative pressure that draws in fresh gas from the circuit, effectively increasing alveolar ventilation and delivering more volatile agent molecules per unit time. Together these accelerate the rise of alveolar partial pressure of the volatile agent.
Option A: Option A is incorrect; nitrogen displacement is not the mechanism of the second gas effect, and vaporizer delivery rate is set independently of alveolar gas composition.
Option B: Option B is incorrect; nitrous oxide has very low blood solubility (blood/gas coefficient 0.47), not high solubility, and its mechanism does not involve altering cardiac output.
Option D: Option D is incorrect; while nitrous oxide does have NMDA antagonist properties contributing to its analgesic effect, the second gas effect is a purely pharmacokinetic phenomenon related to alveolar gas volume and concentration, not a pharmacodynamic receptor interaction.
5. [CASE 2 — QUESTION 5]
A 28-year-old woman with no significant medical history presents for elective rhinoplasty. The anesthesiologist is choosing between sevoflurane and desflurane for inhalational maintenance. She has no history of malignant hyperthermia and no known allergies.
Which of the following best describes the clinically relevant difference between desflurane and sevoflurane with respect to airway properties?
A) Desflurane is preferred for inhalational induction in adults because its lower blood/gas partition coefficient produces faster onset than sevoflurane, and both agents have equivalent airway tolerability at induction concentrations.
B) Sevoflurane causes more bronchospasm than desflurane in patients with reactive airway disease because its higher blood solubility prolongs mucosal contact time in the conducting airways.
C) Desflurane is not suitable for inhalational induction because it is highly pungent and causes airway irritation including coughing, laryngospasm, and breath-holding, particularly at higher concentrations; sevoflurane is non-pungent and well-tolerated for mask induction.
D) Both desflurane and sevoflurane are equally suitable for inhalational induction in adults; the choice between them is determined solely by institutional cost considerations.
ANSWER: C
Rationale:
Option C is correct. Desflurane is the most pungent of the currently used inhaled anesthetics. At concentrations above 1 MAC, it causes significant upper airway irritation, producing coughing, breath-holding, excessive secretions, and laryngospasm, making it unsuitable for inhalational induction. For this reason, desflurane is used for maintenance only, following IV induction with propofol or another agent. Sevoflurane, in contrast, is non-pungent and has a pleasant, non-irritating odor; it is the preferred agent for inhalational induction in both pediatric and adult patients when IV access is not yet established.
Option A: Option A is incorrect: while desflurane does have a lower blood/gas coefficient than sevoflurane (0.45 vs 0.65), its pungency makes it unsuitable for inhalational induction regardless of its kinetic advantage — the two agents do not have equivalent airway tolerability at induction.
Option B: Option B is incorrect: sevoflurane is not associated with more bronchospasm than desflurane; in fact, sevoflurane has bronchodilating properties and is considered safe in patients with reactive airway disease.
Option D: Option D is incorrect: the agents are not equally suitable for inhalational induction; the distinction between desflurane (maintenance only) and sevoflurane (induction and maintenance) is a fundamental clinical pharmacology difference, not merely a cost consideration.
6. [CASE 2 — QUESTION 6]
The anesthesiologist considers adding nitrous oxide to the maintenance regimen for the rhinoplasty patient. A resident asks about contraindications to nitrous oxide use.
Which of the following represents a correct absolute contraindication to nitrous oxide administration?
A) Nitrous oxide is contraindicated when closed, non-compliant gas-containing spaces are present (such as pneumothorax, bowel obstruction, or middle ear surgery with tympanic membrane grafting) because nitrous oxide diffuses into these spaces faster than nitrogen diffuses out, expanding their volume and pressure.
B) Nitrous oxide is contraindicated in all patients undergoing general anesthesia because its NMDA antagonist mechanism increases the risk of emergence delirium when combined with volatile agents.
C) Nitrous oxide is contraindicated in patients with reactive airway disease because its low blood solubility causes rapid deposition on bronchial mucosa, triggering bronchospasm.
D) Nitrous oxide is contraindicated in patients receiving propofol-based total intravenous anesthesia because the two agents competitively inhibit GABA-A receptor binding and produce sub-therapeutic anesthetic depth.
ANSWER: A
Rationale:
Option A is correct. Nitrous oxide has a blood/gas partition coefficient of 0.47, making it approximately 34 times more soluble in blood than nitrogen (coefficient 0.014). When nitrous oxide is administered in the presence of closed, non-compliant gas-filled spaces, it diffuses into those spaces far more rapidly than the resident nitrogen can diffuse out. The net result is expansion of the gas space volume (in compliant cavities such as bowel loops, pneumocephalus, or pneumothorax) or dangerous pressure increase (in non-compliant spaces such as the middle ear). Recognized contraindications include: pneumothorax, significant bowel obstruction or bowel distension, intracranial air (pneumocephalus), middle ear or sinus surgery where gas space pressure changes are hazardous, intraocular gas bubbles (SF6 or C3F8 from retinal surgery), and pulmonary air cysts.
Option B: Option B is incorrect: emergence delirium is not a recognized contraindication to nitrous oxide, and routine combination with volatile agents is standard practice.
Option C: Option C is incorrect: nitrous oxide is not deposited on bronchial mucosa; its airway profile is generally benign, and reactive airway disease is not a contraindication.
Option D: Option D is incorrect: nitrous oxide and propofol act through different mechanisms (NMDA antagonism and GABA-A potentiation respectively) and are not competitive inhibitors; they are commonly used together in TIVA-supplemented techniques.
7. [CASE 2 — QUESTION 7]
During a departmental teaching conference, the attending presents a historical case of severe postoperative hepatitis following repeated halothane anesthesia. The discussion turns to the mechanism of halothane hepatotoxicity.
Which of the following correctly describes the mechanism of halothane-associated fulminant hepatitis?
A) Halothane causes hepatotoxicity through direct dose-dependent mitochondrial toxicity in zone 3 hepatocytes, identical in mechanism to acetaminophen-induced liver failure, and is therefore predictable and avoidable with dose reduction.
B) Halothane hepatotoxicity results from competitive inhibition of cytochrome P450 2E1 by halothane metabolites, preventing normal hepatic drug metabolism and causing accumulation of toxic endogenous substrates.
C) Halothane causes hepatitis through its high lipid solubility, which allows prolonged sequestration in hepatic membranes, producing direct membrane disruption and cholestatic injury independent of immune mechanisms.
D) Halothane undergoes extensive oxidative metabolism by CYP2E1 to trifluoroacetyl chloride, a reactive intermediate that haptenizes hepatic proteins; in susceptible individuals, this triggers an immune-mediated hepatitis upon re-exposure, explaining the characteristic pattern of fever, eosinophilia, and fulminant hepatic necrosis after repeated anesthesia.
ANSWER: D
Rationale:
Option D is correct. Halothane is metabolized by CYP2E1 via oxidative pathways to trifluoroacetyl chloride (TFA chloride), a highly reactive acylating intermediate. TFA chloride covalently modifies hepatic microsomal proteins, creating neoantigens (trifluoroacetylated proteins). In genetically susceptible individuals, this hapten-carrier complex elicits a CD4+ T-cell and antibody-mediated immune response. Upon re-exposure, a rapid and potentially fulminant immune hepatitis develops, characterized clinically by fever, eosinophilia, rash, and severe hepatic necrosis — the syndrome of halothane hepatitis. The immune basis explains why the reaction is not dose-dependent, is far more severe and rapid on re-exposure, and does not occur on every first exposure.
Option A: Option A is incorrect: halothane hepatitis is not dose-dependent and is not mechanistically similar to acetaminophen hepatotoxicity, which is a direct toxic reaction from NAPQI accumulation without an immune component.
Option B: Option B is incorrect: the mechanism is not CYP2E1 inhibition but CYP2E1-mediated bioactivation to a reactive intermediate; the toxicity is not from substrate accumulation but from immune sensitization.
Option C: Option C is incorrect: while halothane has high lipid solubility, the hepatotoxicity mechanism is immunological, not direct membrane disruption, and is not cholestatic in nature.
8. [CASE 2 — QUESTION 8]
A resident asks about the significance of compound A production during sevoflurane anesthesia with low-flow circle systems. The attending explains that compound A is a degradation product formed when sevoflurane contacts carbon dioxide absorbents.
Which of the following best characterizes the current clinical understanding of compound A nephrotoxicity during sevoflurane anesthesia?
A) Compound A is directly nephrotoxic in humans at concentrations routinely achieved during low-flow sevoflurane anesthesia; fresh gas flows below 2 L/min are therefore formally contraindicated by the FDA in all patients.
B) Compound A causes dose-dependent renal tubular injury in rats at high concentrations, but clinical studies in humans have not demonstrated nephrotoxicity at compound A concentrations produced during low-flow sevoflurane anesthesia; the FDA labeling recommends flows of at least 1–2 L/min as a precaution, though sevoflurane at low flows is widely used without evidence of human renal injury.
C) Compound A nephrotoxicity is clinically equivalent to the nephrotoxicity caused by methoxyflurane, and sevoflurane is therefore contraindicated for anesthetics expected to last more than 2 hours.
D) Compound A is formed only when sevoflurane contacts desiccated carbon dioxide absorbents and is completely prevented by using Baralyme rather than soda lime in the breathing circuit.
ANSWER: B
Rationale:
Option B is correct. Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) is produced by the degradation of sevoflurane in the presence of strong base carbon dioxide absorbents (soda lime, Baralyme), particularly at low fresh gas flows and higher absorbent temperatures. In rat studies, high compound A concentrations cause renal tubular necrosis. However, multiple clinical studies in humans have found no evidence of nephrotoxicity at compound A levels generated during low-flow sevoflurane anesthesia, based on sensitive markers of renal tubular function. The FDA label recommends a minimum fresh gas flow of 1–2 L/min as a precautionary measure, but clinical practice widely employs low-flow sevoflurane without observed renal harm. The discrepancy between rat and human toxicity likely reflects species differences in renal metabolism of compound A.
Option A: Option A is incorrect: fresh gas flows below 2 L/min are not formally contraindicated; the FDA provides a precautionary recommendation, not an absolute prohibition, and the evidence for human nephrotoxicity is absent.
Option C: Option C is incorrect: compound A nephrotoxicity is not clinically equivalent to methoxyflurane nephrotoxicity; methoxyflurane caused proven inorganic fluoride-mediated nephrotoxicity that led to its withdrawal, while sevoflurane has not demonstrated this in clinical use.
Option D: Option D is incorrect: compound A is formed with both soda lime and Baralyme (Baralyme actually produces more compound A); using Baralyme does not prevent compound A formation and is not the recommended mitigation strategy.
9. [CASE 3 — QUESTION 9]
A 52-year-old woman with a BMI of 38 kg/m² and a history of severe postoperative nausea and vomiting (PONV) after a previous laparotomy is scheduled for laparoscopic gastric sleeve surgery. The anesthesiologist selects propofol for both IV induction and TIVA maintenance.
Which of the following correctly describes the primary mechanism by which propofol produces general anesthesia?
A) Propofol potentiates inhibitory neurotransmission by positive allosteric modulation of GABA-A receptors, increasing chloride conductance, hyperpolarizing neurons, and producing dose-dependent sedation, hypnosis, and anesthesia.
B) Propofol produces anesthesia by blocking voltage-gated sodium channels in cortical neurons, preventing action potential propagation in a mechanism analogous to local anesthetic agents.
C) Propofol acts primarily as an NMDA receptor antagonist, blocking excitatory glutamatergic transmission in the thalamo-cortical circuits responsible for conscious awareness.
D) Propofol binds to mu-opioid receptors in the periaqueductal gray matter, producing sedation and analgesia through endogenous opioid pathway activation.
ANSWER: A
Rationale:
Option A is correct. Propofol's primary mechanism of action is positive allosteric modulation of GABA-A receptors, the principal ligand-gated chloride channel mediating fast inhibitory synaptic transmission in the CNS. Propofol binds to sites on the GABA-A receptor (distinct from the benzodiazepine binding site) and potentiates GABA-mediated chloride influx, hyperpolarizing the postsynaptic neuron. At higher concentrations, propofol can directly gate the channel in the absence of GABA. The resulting enhancement of inhibitory tone across thalamocortical and corticocortical circuits underlies its dose-dependent spectrum of sedation, hypnosis, and anesthesia.
Option B: Option B is incorrect: sodium channel blockade is the mechanism of local anesthetics (lidocaine, bupivacaine) and is not the primary mechanism of propofol.
Option C: Option C is incorrect: NMDA receptor antagonism is the primary mechanism of ketamine and nitrous oxide, not propofol. Propofol has some minor inhibitory effects on NMDA receptors, but this is not its primary or defining mechanism.
Option D: Option D is incorrect: propofol has no clinically significant activity at opioid receptors; opioid receptor agonism is the mechanism of morphine, fentanyl, and related agents.
10. [CASE 3 — QUESTION 10]
On postoperative day 2, the patient is admitted to the ICU for monitoring. The intensivist continues propofol sedation at 70 mcg/kg/min for 52 hours to facilitate mechanical ventilation. The nursing staff notices new-onset metabolic acidosis, elevated serum lactate, and dark urine.
Which of the following best describes propofol infusion syndrome (PRIS) and its underlying mechanism?
A) PRIS is a predictable, dose-independent reaction caused by propofol's lipid vehicle accumulating in renal tubules, producing osmotic nephrosis and acute kidney injury without metabolic consequences.
B) PRIS results from propofol-mediated inhibition of hepatic gluconeogenesis, causing hypoglycemia, lactic acidosis, and secondary cardiac dysfunction in patients receiving concurrent corticosteroids.
C) PRIS is a potentially fatal syndrome caused by propofol-induced impairment of mitochondrial electron transport chain function and inhibition of free fatty acid oxidation, producing metabolic acidosis, rhabdomyolysis, cardiac failure, and renal failure; risk is highest with infusion rates above 4–5 mg/kg/hr for more than 48 hours, particularly in critically ill patients.
D) PRIS is an immune-mediated hypersensitivity reaction to the egg lecithin component of the propofol emulsion, presenting with anaphylaxis, bronchospasm, and cardiovascular collapse within the first 30 minutes of infusion.
ANSWER: C
Rationale:
Option C is correct. Propofol infusion syndrome is a rare but potentially fatal complication of high-dose, prolonged propofol infusion. The underlying mechanism involves impairment of mitochondrial respiratory chain complex I and II activity, combined with inhibition of beta-oxidation of free fatty acids. The result is a cellular energy failure state characterized by: severe metabolic (lactic) acidosis, lipemic plasma, rhabdomyolysis with elevated creatine kinase and myoglobinuria (explaining the dark urine in this case), acute renal failure, hepatomegaly with elevated transaminases, and refractory cardiac failure including new-onset right bundle branch block or ST-segment changes. Risk factors include infusion rates exceeding 4–5 mg/kg/hr, duration beyond 48 hours, critical illness with high catecholamine states or corticosteroid use, carbohydrate-deficient states, and pediatric patients. Management is immediate discontinuation of propofol and supportive care.
Option A: Option A is incorrect: PRIS is not a dose-independent renal-only reaction from lipid vehicle accumulation; it is a systemic mitochondrial toxicity syndrome with metabolic, cardiac, and renal components.
Option B: Option B is incorrect: propofol does not primarily inhibit gluconeogenesis; the mechanism is mitochondrial electron transport and fatty acid oxidation failure.
Option D: Option D is incorrect: anaphylaxis to egg lecithin is a distinct, separate adverse reaction with an entirely different presentation and time course; it is not PRIS.
11. [CASE 3 — QUESTION 11]
Returning to the original operative plan, the anesthesiologist explains to the surgical team why propofol-based TIVA was specifically chosen over a volatile agent technique for this high-PONV-risk patient.
Which of the following best explains the antiemetic advantage of propofol in the perioperative setting?
A) Propofol reduces PONV by inhibiting serotonin synthesis in enterochromaffin cells of the gut mucosa, reducing the 5-HT3 receptor stimulus that drives chemoreceptor trigger zone activation.
B) Propofol reduces PONV solely through its sedative effect on the cerebral cortex, which decreases cortical awareness of nausea and blunts the conscious perception of emetic stimuli without affecting the vomiting center.
C) Propofol reduces PONV by competitively antagonizing dopamine D2 receptors in the chemoreceptor trigger zone, producing antiemetic effects equivalent to droperidol at standard induction doses.
D) Propofol reduces PONV through a combination of direct antiemetic properties at sub-hypnotic plasma concentrations (likely involving 5-HT3 receptor antagonism and reduced serotonin release) and avoidance of volatile agents, which are independently emetogenic; switching from volatile agent maintenance to propofol TIVA reduces PONV incidence by approximately 30%.
ANSWER: D
Rationale:
Option D is correct. Propofol has antiemetic properties at sub-hypnotic plasma concentrations that are distinct from its sedative effects; these are thought to involve inhibition of serotonin release and possible direct 5-HT3 receptor antagonism, though the precise mechanism remains incompletely characterized. Clinically, propofol-based TIVA reduces PONV incidence by approximately 30% compared to volatile agent-based anesthesia, a finding supported by multiple meta-analyses and embedded in consensus PONV management guidelines. This benefit arises from two simultaneous mechanisms: propofol's own antiemetic properties and the avoidance of volatile agents, which are independently emetogenic. For high-PONV-risk patients (Apfel score 3–4), TIVA with propofol is listed as a risk-reduction strategy alongside pharmacological prophylaxis.
Option A: Option A is incorrect: propofol does not inhibit serotonin synthesis in enterochromaffin cells; this is not the established mechanism of its antiemetic effect.
Option B: Option B is incorrect: the antiemetic effect of propofol is pharmacologically specific and has been demonstrated at sub-hypnotic concentrations where cortical sedation is minimal; it is not merely a sedation-masking effect.
Option C: Option C is incorrect: propofol is not a dopamine D2 antagonist at standard doses; D2 antagonism is the mechanism of droperidol, haloperidol, and metoclopramide, not propofol.
12. [CASE 3 — QUESTION 12]
During induction with propofol 2 mg/kg IV, the patient's blood pressure drops from 138/82 to 88/52 mmHg within 90 seconds. The anesthesiologist administers a bolus of IV fluid and phenylephrine.
Which of the following best explains the mechanism of propofol-induced hypotension at induction?
A) Propofol causes hypotension exclusively through direct myocardial depression, reducing cardiac contractility and stroke volume; heart rate is reflexively increased to compensate but is insufficient to maintain blood pressure.
B) Propofol causes hypotension through a combination of vasodilation (decreased systemic vascular resistance from direct vascular smooth muscle relaxation and reduced sympathetic tone) and mild negative inotropy; the vasodilatory component predominates, and the normal baroreceptor reflex tachycardia is blunted, exacerbating the fall in blood pressure.
C) Propofol causes hypotension by blocking alpha-1 adrenergic receptors in vascular smooth muscle, producing an effect pharmacologically analogous to prazosin that is fully reversible with norepinephrine administration.
D) Propofol hypotension is caused by histamine release from mast cells in the pulmonary vasculature, producing a distributive vasodilatory state that is dose-independent and unpredictable.
ANSWER: B
Rationale:
Option B is correct. Propofol-induced hypotension at induction is multifactorial but predominantly reflects a reduction in systemic vascular resistance (SVR) through vasodilation of arterial and venous capacitance vessels, mediated by direct relaxation of vascular smooth muscle and attenuation of central sympathetic outflow. A mild reduction in myocardial contractility contributes but is not the dominant mechanism. Critically, propofol also blunts the normal baroreceptor reflex: the expected compensatory tachycardia in response to falling blood pressure is attenuated, so heart rate may remain inappropriately normal or only mildly elevated despite significant hypotension. Risk factors for severe propofol hypotension include elderly patients, hypovolemia, rapid injection rate, high baseline sympathetic tone, and concurrent opioid administration.
Option A: Option A is incorrect: while propofol does have mild negative inotropic properties, exclusive myocardial depression is not the primary mechanism; the vasodilatory component and baroreceptor blunting are more important.
Option C: Option C is incorrect: propofol is not a selective alpha-1 adrenergic receptor antagonist; its vasodilatory effect occurs through multiple mechanisms not reducible to alpha-blockade.
Option D: Option D is incorrect: clinically significant histamine release is not a recognized mechanism of propofol-induced hypotension at standard induction doses; it is occasionally associated with anaphylactoid reactions but is not the pharmacological basis of the routine hemodynamic depression seen at induction.
13. [CASE 4 — QUESTION 13]
A 19-year-old male with no IV access arrives in the emergency department following a motor vehicle accident. He is agitated and combative with a suspected open femur fracture. The emergency physician plans to use ketamine for procedural sedation and pain management.
Which of the following best describes ketamine's mechanism of action and the resulting clinical state?
A) Ketamine produces anesthesia through potentiation of GABA-A receptors in the limbic system, creating a state of profound sedation in which patients are unresponsive, apneic, and areflexic, similar to barbiturate anesthesia.
B) Ketamine produces anesthesia by activating mu-opioid receptors in the periaqueductal gray and spinal dorsal horn, creating an analgesic and sedative state that is fully reversible with naloxone.
C) Ketamine produces anesthesia through alpha-2 adrenergic agonism in the locus coeruleus, creating a sedated but arousable state with preserved airway reflexes and minimal cardiovascular depression.
D) Ketamine produces a dissociative anesthetic state through non-competitive antagonism of NMDA receptors, blocking glutamatergic excitatory transmission; the resulting state is characterized by profound analgesia, amnesia, and catalepsy with preserved airway reflexes, spontaneous respirations, and cardiovascular stimulation.
ANSWER: D
Rationale:
Option D is correct. Ketamine's primary mechanism is non-competitive (open-channel) antagonism of NMDA (N-methyl-D-aspartate) glutamate receptors. By blocking ion flux through the NMDA receptor channel, ketamine interrupts thalamo-neocortical and limbic system communication while leaving other subcortical systems relatively intact, producing the distinctive dissociative state: a trancelike catalepsy with profound analgesia, anterograde amnesia, and loss of awareness but preserved and often augmented muscle tone, intact airway protective reflexes, and maintained spontaneous ventilation. Cardiovascular effects are stimulatory through centrally mediated sympathetic activation, making ketamine the induction agent of choice in hemodynamically unstable patients.
Option A: Option A is incorrect: GABA-A potentiation is the mechanism of propofol and benzodiazepines, not ketamine; ketamine produces a dissociative state, not a barbiturate-type unconsciousness with apnea and areflexia.
Option B: Option B is incorrect: while ketamine has some activity at opioid receptors, this is not its primary mechanism of action, and its clinical effects are not reversed by naloxone in a clinically meaningful way.
Option C: Option C is incorrect: alpha-2 adrenergic agonism in the locus coeruleus is the mechanism of dexmedetomidine, not ketamine; dexmedetomidine produces arousable sedation with minimal respiratory depression, which is a distinct profile from ketamine's dissociative state.
14. [CASE 4 — QUESTION 14]
A colleague suggests using ketamine for a 45-year-old patient with a traumatic brain injury (TBI) and suspected elevated intracranial pressure (ICP) who requires emergent airway management. The attending expresses concern about this choice.
Which of the following correctly characterizes ketamine's effect on intracranial pressure and the basis for caution in TBI patients?
A) Ketamine increases cerebral metabolic rate, cerebral blood flow, and ICP through its sympathomimetic and NMDA-mediated cerebrovascular effects; while this concern has been challenged by more recent evidence suggesting ketamine may be safe or even beneficial in ventilated TBI patients, traditional teaching advises caution and the concern should be acknowledged in clinical decision-making.
B) Ketamine is the preferred induction agent in TBI patients with elevated ICP because its NMDA antagonism reduces excitotoxic neuronal injury from glutamate release, providing neuroprotection that outweighs any hemodynamic concerns.
C) Ketamine has no significant effect on ICP when administered with controlled ventilation; the traditional contraindication in head injury is based entirely on animal studies using supraclinical doses and has been formally retracted by major neurosurgical societies.
D) Ketamine lowers ICP through its cardiovascular stimulatory effects, which increase mean arterial pressure and therefore improve cerebral perfusion pressure; it is therefore the agent of choice when ICP is elevated and cerebral perfusion pressure is compromised.
ANSWER: A
Rationale:
Option A is correct and reflects the nuanced current state of evidence. The traditional teaching holds that ketamine raises ICP through increased cerebral metabolic demand, cerebral vasodilation, and elevated cerebral blood flow driven by its sympathomimetic effects. This concern was a longstanding relative contraindication in isolated TBI with elevated ICP. However, more recent literature and systematic reviews have challenged this view, finding no consistent evidence of harm in mechanically ventilated patients with controlled PaCO2; some authors argue ketamine's cardiovascular stimulation may actually maintain cerebral perfusion pressure in hypotensive TBI patients, which is equally critical. The current consensus is nuanced: the classical concern is not without basis, but ketamine is no longer considered absolutely contraindicated in TBI, particularly when alternatives carry greater hemodynamic risk. Clinicians should acknowledge the debate and exercise judgment. Option B is overstated: while NMDA antagonism does have theoretical neuroprotective properties, this has not been established clinically and ketamine is not the formally preferred agent in elevated ICP TBI management.
Option C: Option C is incorrect: stating the contraindication has been "formally retracted" overstates the current evidence; the concern has been re-evaluated, not retracted.
Option D: Option D is incorrect: ketamine does not lower ICP; the cardiovascular stimulation raises MAP and may improve cerebral perfusion pressure, but this is a different consideration from ICP reduction, and this framing would be clinically misleading.
15. [CASE 4 — QUESTION 15]
A 67-year-old septic patient in the ICU requires emergent intubation. The intensivist chooses etomidate for induction. A resident asks about the adrenal suppression associated with etomidate.
Which of the following best describes the mechanism by which etomidate causes adrenal suppression?
A) Etomidate causes adrenal suppression by blocking ACTH receptors on adrenocortical cells, preventing adrenocorticotropic hormone from stimulating cortisol synthesis at the level of the adrenal gland.
B) Etomidate causes adrenal suppression by directly damaging adrenal mitochondria through lipid peroxidation, producing irreversible adrenal cortical necrosis after a single induction dose in critically ill patients.
C) Etomidate inhibits 11-beta-hydroxylase, a key mitochondrial cytochrome P450 enzyme in the steroidogenic pathway, blocking the conversion of 11-deoxycortisol to cortisol; this produces dose-dependent, reversible adrenocortical suppression lasting 4–8 hours after a single induction dose, which is of particular clinical concern in critically ill or septic patients who depend on an intact cortisol stress response.
D) Etomidate causes adrenal suppression through its GABA-A agonist mechanism, which reduces hypothalamic CRH secretion and thereby suppresses the entire hypothalamic-pituitary-adrenal axis in a manner analogous to exogenous glucocorticoid administration.
ANSWER: C
Rationale:
Option C is correct. Etomidate inhibits 11-beta-hydroxylase (CYP11B1), the mitochondrial cytochrome P450 enzyme that catalyzes the final step in cortisol biosynthesis: conversion of 11-deoxycortisol to cortisol. It also inhibits cholesterol side-chain cleavage enzyme (CYP11A1) to a lesser degree. The result is dose-dependent, reversible suppression of cortisol (and to a lesser extent aldosterone) production, lasting approximately 4–8 hours after a single induction dose in healthy patients but potentially longer in the critically ill. In septic patients who already have relative adrenal insufficiency and depend critically on the cortisol stress response for cardiovascular stability and immune regulation, even transient etomidate-induced adrenal suppression has been associated with adverse outcomes in observational studies, though this remains debated. This concern has prompted consideration of alternative induction agents in septic patients requiring intubation.
Option A: Option A is incorrect: etomidate does not block ACTH receptors; ACTH binds normally and triggers the signaling cascade, but the downstream enzymatic step is blocked.
Option B: Option B is incorrect: etomidate-induced adrenal suppression is reversible and enzymatic, not from mitochondrial damage or adrenal necrosis.
Option D: Option D is incorrect: etomidate's adrenal suppression is a direct peripheral enzymatic effect on the adrenal cortex, not a central hypothalamic-pituitary axis suppression mediated by its GABA-A mechanism.
16. [CASE 4 — QUESTION 16]
The same septic patient has a blood pressure of 74/40 mmHg despite 2L of IV crystalloid. The team debates whether the cardiovascular profile of etomidate justifies its use over propofol for induction.
Which of the following best explains why etomidate is preferred over propofol for induction in hemodynamically unstable patients?
A) Etomidate is preferred because it produces reflex tachycardia through vagal inhibition, increasing heart rate and cardiac output to compensate for any vasodilatory effect during induction.
B) Etomidate produces minimal cardiovascular depression because it does not significantly reduce systemic vascular resistance, cardiac contractility, or heart rate at induction doses; its hemodynamic stability distinguishes it from propofol, which causes vasodilation and blunts baroreceptor reflexes, and from ketamine, whose sympathomimetic effects may be unreliable in catecholamine-depleted patients.
C) Etomidate is preferred in hemodynamically unstable patients because it releases endogenous catecholamines from adrenal chromaffin cells, producing a brief period of sympathetic stimulation that offsets induction-related hypotension.
D) Etomidate is preferred because it activates alpha-2 adrenergic receptors in the vasomotor center, increasing sympathetic outflow and maintaining vascular tone during the induction period.
ANSWER: B
Rationale:
Option B is correct. Etomidate is uniquely distinguished among IV induction agents by its minimal cardiovascular effects. At standard induction doses (0.2–0.3 mg/kg IV), etomidate produces virtually no change in heart rate, systemic vascular resistance, mean arterial pressure, or cardiac output. This cardiovascular neutrality is the primary reason etomidate is favored for induction in hemodynamically compromised patients — including those with hemorrhagic shock, septic shock, severe aortic stenosis, or decompensated heart failure. Propofol, by contrast, reliably causes vasodilation and baroreceptor blunting, producing clinically significant hypotension in volume-depleted or low-cardiac-reserve patients. Ketamine's cardiovascular stimulation from central sympathetic activation is a useful property, but in catecholamine-depleted states (as can occur in severe prolonged sepsis), the endogenous catecholamine stores may be exhausted and ketamine can then paradoxically cause cardiovascular depression.
Option A: Option A is incorrect: etomidate does not produce reflex tachycardia through vagal inhibition; it has no significant chronotropic mechanism of action.
Option C: Option C is incorrect: etomidate does not stimulate catecholamine release from adrenal chromaffin cells; that is not a recognized mechanism of its hemodynamic stability.
Option D: Option D is incorrect: etomidate is not an alpha-2 adrenergic agonist; alpha-2 agonism is the mechanism of dexmedetomidine and clonidine.
17. [CASE 5 — QUESTION 17]
A 71-year-old male with obstructive sleep apnea is scheduled for elective cervical spine surgery requiring awake fiberoptic intubation. The anesthesiologist plans to use dexmedetomidine as the primary sedative agent during the awake intubation phase.
Which of the following best describes the mechanism by which dexmedetomidine produces sedation?
A) Dexmedetomidine produces sedation by potentiating GABA-A receptor-mediated inhibitory neurotransmission in the thalamo-cortical circuits, in a mechanism similar to but more selective than benzodiazepines.
B) Dexmedetomidine produces sedation through highly selective agonism at alpha-2 adrenergic receptors in the locus coeruleus, the principal noradrenergic nucleus; activation of these receptors inhibits norepinephrine release and reduces ascending arousal drive, producing a sedated state that resembles natural sleep and from which patients are readily arousable.
C) Dexmedetomidine produces sedation through NMDA receptor antagonism in the prefrontal cortex, disrupting thalamocortical integration and producing a dissociative state with preserved muscle tone and airway reflexes.
D) Dexmedetomidine produces sedation by activating mu-opioid receptors in the ventrolateral preoptic area of the hypothalamus, the sleep-promoting region, suppressing the ascending arousal system through endogenous opioid pathway stimulation.
ANSWER: B
Rationale:
Option B is correct. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist with an alpha-2 to alpha-1 selectivity ratio of approximately 1,600:1, far exceeding that of clonidine (approximately 200:1). Its sedative mechanism operates primarily through alpha-2A receptor agonism in the locus coeruleus (LC), the brainstem's primary noradrenergic nucleus and a key regulator of arousal. Activation of presynaptic alpha-2 receptors in the LC inhibits adenylyl cyclase, reduces norepinephrine release, and decreases the firing of LC neurons, thereby diminishing ascending noradrenergic arousal drive to the thalamus and cortex. The resulting sedated state closely resembles the neurophysiology of natural non-REM sleep — patients are sedated but arousable and cooperative with gentle stimulation — a property that makes dexmedetomidine uniquely useful for procedures requiring patient participation, such as awake fiberoptic intubation.
Option A: Option A is incorrect: GABA-A potentiation is the mechanism of benzodiazepines, propofol, and barbiturates; dexmedetomidine's mechanism is adrenergic, not GABAergic.
Option C: Option C is incorrect: NMDA antagonism producing a dissociative state is the mechanism of ketamine, not dexmedetomidine.
Option D: Option D is incorrect: dexmedetomidine does not activate mu-opioid receptors; its mechanism is adrenergic, and its sedation is not opioid-mediated or reversed by naloxone.
18. [CASE 5 — QUESTION 18]
During the awake fiberoptic intubation, dexmedetomidine is infused at 0.7 mcg/kg/hr following a loading dose. The patient is sedated, eyes closed, but opens eyes and follows simple commands when asked. His oxygen saturation remains 97% on supplemental oxygen via nasal cannula.
Which of the following best explains why dexmedetomidine is preferred over midazolam for sedation during awake fiberoptic intubation?
A) Dexmedetomidine is preferred because it produces deeper sedation than midazolam, ensuring the patient is completely unresponsive to the discomfort of scope passage, which prevents unexpected patient movement during intubation.
B) Dexmedetomidine is preferred because it provides superior topical anesthesia of the larynx compared to midazolam, reducing the need for supplemental local anesthetic application during fiberoptic intubation.
C) Dexmedetomidine is preferred because it is a more potent amnestic than midazolam, ensuring no recall of the intubation procedure without producing any sedation that might compromise patient cooperation.
D) Dexmedetomidine produces a sedated but arousable and cooperative state with minimal respiratory depression at standard infusion rates, allowing the patient to follow commands, maintain their own airway, and breathe spontaneously throughout the procedure; this profile is ideally suited to awake fiberoptic intubation, where patient cooperation and preserved ventilation are both essential.
ANSWER: D
Rationale:
Option D is correct. The defining clinical advantage of dexmedetomidine for awake fiberoptic intubation is the unique combination of meaningful sedation with preserved arousability and minimal respiratory depression. Because dexmedetomidine's sedation operates through the locus coeruleus noradrenergic pathway rather than through direct respiratory center depression, it does not cause the dose-dependent respiratory depression characteristic of benzodiazepines and opioids. Patients remain cooperative when gently stimulated, can follow commands such as "take a deep breath" or "open wide," and continue to breathe spontaneously throughout the procedure. Benzodiazepines like midazolam, even at modest anxiolytic doses, can produce paradoxical disinhibition or, more commonly, respiratory depression and loss of upper airway tone that is particularly problematic in patients with difficult airways or obstructive sleep apnea.
Option A: Option A is incorrect and describes the wrong clinical goal: the objective of dexmedetomidine in awake fiberoptic intubation is not complete unresponsiveness but cooperative, arousable sedation that preserves the patient's ability to participate and protect their airway.
Option B: Option B is incorrect: dexmedetomidine provides sedation and anxiolysis but does not provide topical laryngeal anesthesia; local anesthetic application (lidocaine spray or nerve blocks) remains essential regardless of the sedative used.
Option C: Option C is incorrect: dexmedetomidine is not primarily an amnestic agent, and producing amnesia while avoiding sedation is not its clinical role in this context; benzodiazepines are the agents with reliable amnestic properties.
19. [CASE 5 — QUESTION 19]
Ten minutes into the dexmedetomidine loading dose infusion, the patient develops a heart rate of 44 bpm and blood pressure of 86/52 mmHg.
Which of the following best explains these hemodynamic findings?
A) Dexmedetomidine causes bradycardia and hypotension through alpha-2 receptor-mediated reduction of central sympathetic outflow, decreasing norepinephrine release and lowering both heart rate and systemic vascular resistance; at higher loading doses, transient hypertension from peripheral alpha-2B receptor-mediated vasoconstriction may precede the sustained hypotension.
B) Dexmedetomidine causes bradycardia through direct blockade of cardiac beta-1 adrenergic receptors, reducing sinoatrial node automaticity; hypotension results from secondary reduction in cardiac output with no effect on vascular tone.
C) Dexmedetomidine causes hypotension through histamine release from cardiac mast cells, producing vasodilation and a reflex increase in heart rate; the observed bradycardia suggests an idiosyncratic reaction unrelated to its alpha-2 mechanism.
D) Dexmedetomidine causes hemodynamic depression by inhibiting voltage-gated calcium channels in cardiac and vascular smooth muscle, producing effects pharmacologically similar to diltiazem at high plasma concentrations.
ANSWER: A
Rationale:
Option A is correct. The cardiovascular adverse effects of dexmedetomidine — bradycardia and hypotension — are direct pharmacological consequences of its alpha-2 agonist mechanism. Alpha-2 receptor activation in the locus coeruleus and brainstem sympathetic centers reduces central sympathetic outflow, decreasing norepinephrine release at cardiac and vascular synaptic terminals. The result is reduced heart rate (decreased sinoatrial node firing from reduced sympathetic drive and enhanced vagal tone) and reduced systemic vascular resistance (decreased arterial vasomotor tone). A biphasic blood pressure response is classically described with loading doses: initial transient hypertension from activation of peripheral vascular alpha-2B receptors (which mediate smooth muscle contraction) followed by the more sustained hypotension from central sympatholysis. Clinically, bradycardia and hypotension are the most common adverse effects requiring dose reduction or treatment; atropine or glycopyrrolate may be used for significant bradycardia.
Option B: Option B is incorrect: dexmedetomidine is not a beta-1 adrenergic receptor blocker; its bradycardia is mediated through reduced sympathetic tone and enhanced vagal tone, not direct beta blockade.
Option C: Option C is incorrect: histamine release is not a mechanism of dexmedetomidine's hemodynamic effects, and reflex tachycardia would not be expected given the central sympatholytic action.
Option D: Option D is incorrect: dexmedetomidine does not inhibit voltage-gated calcium channels; calcium channel blockade is the mechanism of diltiazem, verapamil, and dihydropyridine agents.
20. [CASE 5 — QUESTION 20]
A colleague asks in what other clinical scenarios dexmedetomidine's unique sedation profile makes it the preferred agent over benzodiazepines or propofol.
Which of the following best describes a clinical context in which dexmedetomidine's sedation profile provides a meaningful advantage over alternative agents?
A) Dexmedetomidine is preferred for rapid sequence induction in morbidly obese patients because its minimal respiratory depression allows continued spontaneous ventilation during the apneic period between induction and intubation.
B) Dexmedetomidine is preferred for maintenance of general anesthesia as a sole agent because it provides sufficient depth to prevent intraoperative awareness without requiring supplemental opioids or volatile agents.
C) Dexmedetomidine is preferred for ICU sedation in mechanically ventilated patients in whom daily awakening trials are planned, because its arousable sedation profile facilitates rapid transition from sedated to awake without prolonged emergence, reducing time on mechanical ventilation and ICU length of stay compared to benzodiazepine-based sedation.
D) Dexmedetomidine is preferred as the sole premedication for patients with severe anxiety before general anesthesia because its amnestic properties reliably prevent any recall of the perioperative period, including events occurring before induction.
ANSWER: C
Rationale:
Option C is correct. ICU sedation with daily awakening trials (spontaneous awakening trials, SAT) is one of the strongest evidence-based indications for dexmedetomidine. The MENDS and SLEAP trials demonstrated that dexmedetomidine-based sedation, compared to benzodiazepine (lorazepam or midazolam) infusions, was associated with more time at target sedation level, shorter duration of mechanical ventilation, and reduced delirium incidence in mechanically ventilated ICU patients. The arousable, cooperative sedation profile of dexmedetomidine allows patients to be assessed neurologically, perform daily awakening trials, and respond to weaning trials without prolonged and unpredictable emergence from a deep sedative state, as occurs with benzodiazepine accumulation.
Option A: Option A is incorrect: dexmedetomidine is not used for rapid sequence induction; the apneic period in RSI requires a true induction agent (propofol, etomidate, ketamine), and dexmedetomidine's slow onset and hemodynamic effects make it inappropriate for this role.
Option B: Option B is incorrect: dexmedetomidine cannot be used as a sole general anesthetic; it provides sedation and analgesia but does not produce sufficient depth to prevent awareness under surgical stimulation without supplemental agents.
Option D: Option D is incorrect: dexmedetomidine is not a reliable amnestic agent; benzodiazepines (midazolam) have superior and better-characterized amnestic properties, and dexmedetomidine is not used primarily for perioperative amnesia.
21. [CASE 6 — QUESTION 21]
A 44-year-old non-smoking woman with a history of PONV after a previous laparoscopic procedure is scheduled for elective laparoscopic hysterectomy. The anesthesiologist performs a pre-anesthetic PONV risk assessment using the Apfel simplified risk score.
Which of the following correctly identifies the four components of the Apfel simplified risk score and their clinical utility?
A) The Apfel score assigns one point each for: age over 50, BMI over 30, anticipated surgery duration over 2 hours, and use of volatile anesthetic agents; a score of 3 or 4 indicates high risk and mandates TIVA.
B) The Apfel score assigns one point each for: history of motion sickness, opioid-naive status, male sex, and use of nitrous oxide; a score of 2 or higher warrants single-agent antiemetic prophylaxis.
C) The Apfel score assigns one point each for: female sex, non-smoker status, history of PONV or motion sickness, and anticipated postoperative opioid use; patients with 0, 1, 2, 3, or 4 risk factors have PONV incidences of approximately 10%, 20%, 40%, 60%, and 80% respectively, with scores of 3–4 defining high-risk patients warranting multimodal prophylaxis.
D) The Apfel score assigns one point each for: age under 40, ASA physical status III or IV, use of regional anesthesia, and duration of surgery under 1 hour; scores above 2 indicate the need for prophylactic antiemetic administration before induction.
ANSWER: C
Rationale:
Option C is correct. The Apfel simplified risk score, validated in a large multicenter cross-validation study, uses four independent predictors of PONV, each assigned one point: (1) female sex, (2) non-smoker status, (3) personal history of PONV or motion sickness, and (4) anticipated postoperative opioid use. The corresponding PONV incidences for scores of 0 through 4 are approximately 10%, 20%, 40%, 60%, and 80%. This patient scores 3 (female, non-smoker, history of PONV), placing her in the high-risk category. Consensus guidelines (Gan et al., 2014) recommend multimodal prophylaxis targeting at least two receptor systems for scores of 3 or 4, and consideration of TIVA with propofol as an anesthetic risk-reduction strategy.
Option A: Option A is incorrect: the Apfel score does not include age, BMI, or surgery duration; these are not the validated predictors.
Option B: Option B is incorrect: motion sickness history is a valid predictor, but male sex is not — female sex is the risk factor; opioid-naive status is also incorrect.
Option D: Option D is incorrect: ASA status, regional anesthesia use, and surgery duration are not components of the Apfel score.
22. [CASE 6 — QUESTION 22]
The anesthesiologist learns that the patient has a first-degree relative who suffered a malignant hyperthermia (MH) crisis during surgery. Genetic testing has not been performed. The team discusses anesthetic technique selection.
Which of the following best describes the appropriate anesthetic plan and its pharmacological rationale?
A) TIVA with propofol and remifentanil is the appropriate technique because all potent volatile halogenated agents (sevoflurane, desflurane, isoflurane) and succinylcholine are MH triggers and are absolutely contraindicated in susceptible individuals; propofol, non-depolarizing neuromuscular blockers, opioids, benzodiazepines, and nitrous oxide are all considered safe in MH-susceptible patients.
B) The patient should receive a volatile agent technique with sevoflurane because sevoflurane has the lowest reported rate of MH triggering among the halogenated agents, and the risk in a first-degree relative without confirmed genetic susceptibility is below the threshold requiring avoidance.
C) The patient should receive a volatile agent technique with desflurane because its low blood solubility allows rapid offset, minimizing cumulative volatile agent exposure and thereby reducing MH trigger risk compared to agents with higher solubility.
D) TIVA is required only if the patient personally tests positive on the caffeine-halothane contracture test; first-degree family history alone does not alter anesthetic agent selection under current guidelines.
ANSWER: A
Rationale:
Option A is correct. Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder of skeletal muscle calcium regulation, most commonly involving mutations in the ryanodine receptor 1 (RYR1) gene. The established MH triggers are: all potent halogenated volatile anesthetic agents (halothane, isoflurane, sevoflurane, desflurane, enflurane) and succinylcholine (the only depolarizing neuromuscular blocker in clinical use). In an individual with a first-degree relative who has experienced an MH crisis, MH susceptibility must be assumed until proven otherwise — the risk is too high to accept the use of any trigger agent. TIVA with propofol, opioids (remifentanil, fentanyl), non-depolarizing neuromuscular blockers (rocuronium, vecuronium), benzodiazepines, and nitrous oxide is the safe technique of choice, as none of these agents triggers MH. The anesthesia machine must also be prepared by flushing with high-flow oxygen and replacing the circuit to minimize residual volatile agent contamination.
Option B: Option B is incorrect: no halogenated volatile agent is safer than another with respect to MH triggering — all are equally contraindicated.
Option C: Option C is incorrect for the same reason; blood solubility has no bearing on MH trigger risk, which is pharmacodynamic, not pharmacokinetic.
Option D: Option D is incorrect: first-degree family history of confirmed MH is sufficient indication to use a trigger-free anesthetic without requiring the patient's personal positive contracture test.
23. [CASE 6 — QUESTION 23]
During the TIVA technique, remifentanil is selected as the opioid component of the propofol-based regimen. The resident asks why remifentanil is preferred over fentanyl as the opioid component in TIVA.
Which of the following best explains the pharmacokinetic advantage of remifentanil in TIVA?
A) Remifentanil is preferred because its high lipid solubility allows rapid CNS penetration, producing faster onset than fentanyl; both agents have similar context-sensitive half-times after prolonged infusions.
B) Remifentanil is preferred because it is primarily eliminated by renal excretion, making its offset predictable and independent of hepatic function, which may be impaired in surgical patients receiving prolonged anesthesia.
C) Remifentanil is preferred because it undergoes zero-order kinetics at clinical doses, meaning its plasma concentration declines linearly after infusion cessation regardless of infusion duration, allowing precise prediction of emergence time.
D) Remifentanil is preferred because it is metabolized by nonspecific plasma and tissue esterases rather than by hepatic cytochrome P450 enzymes; this produces an ultra-short context-sensitive half-time of approximately 3–5 minutes that is essentially independent of infusion duration, enabling rapid, predictable titration of analgesia and very fast offset at emergence regardless of how long the infusion has run.
ANSWER: D
Rationale:
Option D is correct. Remifentanil's defining pharmacokinetic property is its metabolism by nonspecific esterases (primarily in blood, muscle, and intestinal wall tissue) rather than by hepatic CYP enzymes. This ester hydrolysis produces a context-sensitive half-time — the time for plasma concentration to fall 50% after stopping an infusion — of approximately 3–5 minutes, a value that remains essentially constant regardless of infusion duration. This is in stark contrast to fentanyl and sufentanil, whose context-sensitive half-times increase markedly with infusion duration as the drugs accumulate in peripheral tissue compartments and then redistribute back into plasma after the infusion stops. The practical consequence for TIVA is that remifentanil allows continuous, fine-grained titration of analgesia throughout surgery and produces very rapid, predictable offset at emergence, facilitating extubation timing without concern about residual opioid effect.
Option A: Option A is incorrect: fentanyl and remifentanil have different context-sensitive half-times — this is precisely the pharmacokinetic distinction that makes remifentanil superior for TIVA.
Option B: Option B is incorrect: remifentanil is metabolized by tissue esterases, not renally excreted; renal function does not significantly alter its offset.
Option C: Option C is incorrect: remifentanil does not follow zero-order kinetics; it undergoes first-order ester hydrolysis, and its context-sensitive half-time is the relevant parameter, not zero-order kinetics.
24. [CASE 6 — QUESTION 24]
In addition to TIVA, the anesthesiologist administers ondansetron 4 mg IV and dexamethasone 8 mg IV as PONV prophylaxis. A student asks why ondansetron is given near the end of surgery while dexamethasone was given at induction.
Which of the following best explains the timing difference between these two antiemetics?
A) Ondansetron is given at induction because its slow hepatic metabolism requires a long lead time to achieve therapeutic plasma concentrations; dexamethasone is given at the end of surgery because its mechanism requires direct contact with post-surgical wound tissue.
B) Ondansetron is most effective against early PONV (first 6 hours) and has a duration of approximately 4–6 hours; administering it near the end of surgery aligns its peak effect with the highest-risk early postoperative period. Dexamethasone has a delayed onset of antiemetic effect (approximately 1–2 hours) and is given at induction to ensure its effect is established by the time the patient reaches the recovery room.
C) Ondansetron is given at the end of surgery to avoid its known intraoperative side effect of QTc prolongation at induction doses; dexamethasone is given at induction because early administration prevents intraoperative bronchospasm triggered by volatile anesthetic exposure.
D) Both agents have identical pharmacokinetic profiles; the timing difference is based purely on institutional protocol rather than pharmacological rationale, and both would be equally effective if given at any point during the anesthetic.
ANSWER: B
Rationale:
Option B is correct. The timing difference between ondansetron and dexamethasone for PONV prophylaxis is based directly on their respective pharmacokinetic profiles and onset characteristics. Ondansetron, a 5-HT3 receptor antagonist, has an onset within 30 minutes of IV administration but a relatively short duration of antiemetic effect of approximately 4–6 hours. Administering it near the end of surgery (typically 15–30 minutes before anticipated emergence) aligns its peak and sustained activity with the early postoperative period when PONV risk is highest. Dexamethasone's antiemetic mechanism — which likely involves reduction of central serotonin release, prostaglandin inhibition, and anti-inflammatory effects on vagal afferents — has a delayed onset of approximately 1–2 hours after IV administration. For this reason, dexamethasone must be given at or shortly after induction to ensure its antiemetic effect is fully established by the time the patient emerges and enters the recovery room.
Option A: Option A is incorrect: ondansetron does not require a long lead time and is not given at induction; dexamethasone's mechanism is not mediated through wound tissue contact.
Option C: Option C is incorrect: QTc prolongation is a recognized concern with ondansetron at higher doses, but this is not the reason for end-of-surgery timing, and bronchospasm prevention is not a rationale for early dexamethasone in this context.
Option D: Option D is incorrect: the timing difference is pharmacologically driven and clinically meaningful, not arbitrary.
25. [CASE 7 — QUESTION 25]
A 38-year-old man with high dental anxiety is scheduled for extraction of all four wisdom teeth under general anesthesia in an outpatient surgical center. He reports extreme preoperative anxiety and asks for something to help him relax before going to the operating room. The anesthesiologist administers midazolam 2 mg IV approximately 20 minutes before induction.
Which of the following best describes the mechanism and clinically relevant properties of midazolam as a preanesthetic medication?
A) Midazolam reduces preoperative anxiety by blocking cortisol release from the adrenal cortex, attenuating the stress-response-driven anxiety that would otherwise require higher induction doses of propofol.
B) Midazolam produces anxiolysis, sedation, and anterograde amnesia through positive allosteric modulation of GABA-A receptors at the benzodiazepine binding site, enhancing chloride conductance; it reduces MAC of subsequently administered volatile agents and produces reliable anterograde amnesia for perioperative events, making it the most widely used perioperative anxiolytic.
C) Midazolam produces preoperative anxiolysis through selective serotonin reuptake inhibition in the amygdala, reducing fear circuitry activation; its onset is faster than other SSRIs because of its water-soluble prodrug formulation that allows IV administration.
D) Midazolam reduces preoperative anxiety through mu-opioid receptor partial agonism in the limbic system, providing anxiolysis and mild analgesia; its effects are fully reversed by naloxone, which is available in the PACU for reversal if excessive sedation occurs.
ANSWER: B
Rationale:
Option B is correct. Midazolam is a short-acting benzodiazepine that produces its clinical effects through positive allosteric modulation of GABA-A receptors at the specific benzodiazepine recognition site (the interface between the alpha and gamma subunits), enhancing the frequency of chloride channel opening in response to GABA and increasing inhibitory tone across CNS circuits mediating anxiety, memory consolidation, and arousal. Its clinical profile for preanesthetic use is characterized by: rapid IV onset (1–2 minutes), reliable anxiolysis, anterograde amnesia (preventing encoding of new memories after drug administration, so patients typically have no recall of IV placement, transport to the OR, or placement of monitoring), mild sedation, and an anesthetic-sparing effect (reducing MAC of subsequently administered volatile agents by approximately 25–40% at standard premedication doses). Its water-soluble formulation at injection pH (it ring-closes to a lipophilic form at physiological pH) contributes to its reliable IV pharmacokinetics.
Option A: Option A is incorrect: midazolam does not block adrenal cortisol release; that is a property of etomidate.
Option C: Option C is incorrect: midazolam is not an SSRI and has no serotonergic mechanism; SSRIs are used for chronic anxiety disorders, not acute perioperative anxiolysis.
Option D: Option D is incorrect: midazolam is a benzodiazepine, not an opioid; it has no mu-receptor activity and is not reversed by naloxone; its reversal agent is flumazenil.
26. [CASE 7 — QUESTION 26]
A 34-year-old woman at 36 weeks gestation presents for emergency cesarean section. She last ate a full meal 3 hours ago. The anesthesiologist administers sodium citrate 30 mL orally immediately before induction as part of aspiration prophylaxis.
Which of the following best explains the pharmacological rationale for sodium citrate in this setting?
A) Sodium citrate reduces aspiration risk by accelerating gastric emptying through stimulation of antral smooth muscle via citrate ion interaction with enteric serotonin receptors, reducing gastric volume before induction.
B) Sodium citrate reduces aspiration risk by competitively inhibiting gastric parietal cell H+/K+ ATPase, suppressing ongoing acid secretion and raising gastric pH within 15 minutes of oral administration.
C) Sodium citrate reduces aspiration risk by forming an insoluble precipitate with gastric pepsin, inactivating the proteolytic component of gastric contents and reducing mucosal injury if aspiration occurs.
D) Sodium citrate acts as a non-particulate antacid that directly neutralizes existing gastric acid through chemical buffering, rapidly raising gastric pH above 2.5 within minutes of administration; being non-particulate, it does not itself cause pulmonary injury if aspirated, unlike particulate antacids such as magnesium trisilicate.
ANSWER: D
Rationale:
Option D is correct. Sodium citrate 0.3 M (30 mL oral solution) is a non-particulate liquid antacid that directly neutralizes gastric acid through acid-base chemistry within minutes of ingestion. Raising gastric pH above 2.5 is the critical pharmacological goal: at pH above this threshold, aspirated gastric fluid causes substantially less chemical pneumonitis (Mendelson syndrome) than highly acidic gastric contents. The essential advantage over particulate antacids (such as magnesium trisilicate or aluminum hydroxide suspensions) is that sodium citrate, if aspirated along with gastric contents, does not itself cause pulmonary injury; particulate antacids, by contrast, cause granulomatous pulmonary inflammation when aspirated, potentially worsening the aspiration injury. For emergency procedures in patients who have recently eaten (as in this obstetric case), sodium citrate is given immediately before induction because its effect is rapid (unlike H2 blockers, which take 30–60 minutes to reduce further acid secretion, and PPIs, which take hours).
Option A: Option A is incorrect: sodium citrate does not accelerate gastric emptying; prokinetic agents (metoclopramide) serve that role.
Option B: Option B is incorrect: H+/K+ ATPase inhibition is the mechanism of proton pump inhibitors such as omeprazole and pantoprazole, not sodium citrate; sodium citrate neutralizes existing acid chemically rather than suppressing its production.
Option C: Option C is incorrect: sodium citrate does not precipitate pepsin; its mechanism is purely acid-base neutralization.
27. [CASE 7 — QUESTION 27]
The anesthesiologist also administers metoclopramide 10 mg IV as part of the aspiration prophylaxis regimen for the obstetric patient. A student asks about metoclopramide's mechanism and when it should not be used.
Which of the following best describes metoclopramide's mechanism of action and its principal contraindications?
A) Metoclopramide accelerates gastric emptying and increases lower esophageal sphincter tone through combined dopamine D2 receptor antagonism and serotonin 5-HT4 receptor agonism in the gut; it is contraindicated in mechanical bowel obstruction (where increased motility risks perforation) and pheochromocytoma (where D2 blockade at the adrenal medulla can precipitate a hypertensive crisis).
B) Metoclopramide accelerates gastric emptying through selective muscarinic M3 receptor agonism at the gastric antrum, increasing antral contractility; it is contraindicated in patients with myasthenia gravis due to the risk of cholinergic crisis.
C) Metoclopramide accelerates gastric emptying through alpha-1 adrenergic receptor stimulation of pyloric smooth muscle, reducing pyloric resistance; it is contraindicated in patients with hypertension because its sympathomimetic mechanism can precipitate hypertensive urgency.
D) Metoclopramide reduces gastric volume by inhibiting gastric acid secretion through H2 receptor antagonism while simultaneously stimulating antral motility through a separate peripheral beta-2 adrenergic mechanism; it is contraindicated in patients with a history of prolonged QTc.
ANSWER: A
Rationale:
Option A is correct. Metoclopramide is a prokinetic and antiemetic agent with a dual mechanism. Its prokinetic effects in the upper GI tract arise from: (1) dopamine D2 receptor antagonism in the enteric nervous system, which removes dopamine's inhibitory effect on gastric motility and accelerates antral contractions and pyloric relaxation; and (2) serotonin 5-HT4 receptor agonism, which augments the prokinetic cholinergic reflex and enhances coordinated peristalsis. These combined effects increase gastric emptying rate, raise lower esophageal sphincter tone, and reduce gastric volume. Centrally, D2 antagonism at the chemoreceptor trigger zone (area postrema) provides antiemetic activity. Key contraindications include: (1) mechanical bowel obstruction or gastrointestinal perforation, where prokinetic stimulation of gut motility risks mechanical disruption or worsening perforation; (2) pheochromocytoma, where dopamine D2 blockade at chromaffin cells can reduce the inhibitory dopaminergic brake on catecholamine secretion and precipitate a hypertensive crisis; and (3) concurrent use of drugs with significant extrapyramidal or dopamine-depleting activity.
Option B: Option B is incorrect: metoclopramide's mechanism is not muscarinic M3 agonism; that would describe bethanechol.
Option C: Option C is incorrect: alpha-1 adrenergic stimulation is not the mechanism; metoclopramide's prokinetic effect is dopaminergic and serotonergic.
Option D: Option D is incorrect: metoclopramide has no H2 receptor antagonist or beta-2 adrenergic activity; those mechanisms describe entirely different drug classes.
28. [CASE 7 — QUESTION 28]
The anesthesiologist considers glycopyrrolate as a premedication antisialagogue for an elderly patient with obstructive sleep apnea undergoing awake fiberoptic intubation, and explains to the resident why glycopyrrolate is preferred over atropine in this setting.
Which of the following best explains the pharmacological basis for preferring glycopyrrolate over atropine when central anticholinergic effects must be avoided?
A) Glycopyrrolate is preferred because it has a shorter duration of action than atropine, reducing the total cumulative anticholinergic exposure at muscarinic receptors in the brain during the perioperative period.
B) Glycopyrrolate is preferred because it is more potent than atropine at peripheral muscarinic receptors in salivary glands, achieving superior antisialagogue effect at lower doses and thus reducing total drug exposure.
C) Glycopyrrolate is preferred because it is a quaternary ammonium compound that does not cross the blood-brain barrier, confining its muscarinic blockade to peripheral tissues; atropine and scopolamine are tertiary amines that cross the blood-brain barrier freely and produce central anticholinergic effects including sedation, confusion, and delirium — effects that are particularly hazardous in elderly patients and those at risk for emergence delirium.
D) Glycopyrrolate is preferred because it selectively blocks M1 and M3 muscarinic receptor subtypes in peripheral glands and smooth muscle while sparing M2 receptors in the heart and CNS, providing antisialagogue effects without bradycardia or central effects.
ANSWER: C
Rationale:
Option C is correct. The critical pharmacological distinction between glycopyrrolate and atropine (and scopolamine) is their chemical structure and the consequent difference in CNS penetration. Glycopyrrolate is a quaternary ammonium compound: its permanent positive charge at physiological pH renders it highly water-soluble and essentially impermeable to the blood-brain barrier (BBB). As a result, glycopyrrolate's muscarinic blockade is confined to peripheral sites — salivary glands (antisialagogue effect), gut, heart, and bronchi — without significant CNS activity. Atropine and scopolamine are tertiary amines: they are lipophilic and cross the BBB readily. At the doses used perioperatively, these agents block muscarinic receptors in the CNS, producing sedation, confusion, impaired short-term memory, and in vulnerable patients (elderly, those with baseline cognitive impairment, high-risk delirium populations) frank anticholinergic delirium or the central anticholinergic syndrome. For patients undergoing awake fiberoptic intubation — where a cooperative, oriented patient is essential — and for elderly patients at risk for postoperative delirium, glycopyrrolate is the antisialagogue of choice.
Option A: Option A is incorrect: duration of action is not the primary rationale; the BBB impermeability is the key distinction.
Option B: Option B is incorrect: peripheral potency differences are not the clinical rationale for preferring glycopyrrolate in this setting.
Option D: Option D is incorrect: glycopyrrolate does not selectively spare M2 receptors; it is a non-selective muscarinic antagonist at peripheral sites, and the absence of subtype selectivity is not its distinguishing feature — BBB impermeability is.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.